Hibsago Approved for Chronic Hepatitis B, With Functional Cure Limited to a Subset

FDA approved GSK and Ionis’ bepirovirsen (Hibsago) for eligible adults with chronic HBV without cirrhosis, alongside existing antivirals. Phase III functional cure was reported in 19% overall versus none on placebo and 26% among patients with lower baseline surface antigen; durability, monitoring, access, and safe antiviral discontinuation remain follow-up questions.